A Glossary of Psychedelic-Policy Terms

The public conversation around psychedelic policy is growing rapidly, but the vocabulary used in legal and scientific circles can be confusing. Words like "decriminalisation" and "legalisation" are often used interchangeably in casual debate, though they mean very different things in law. In South Africa, psilocybin is currently listed as a Schedule 7 substance under the Medicines and Related Substances Act, which imposes strict prohibitions. Understanding the precise terminology is essential for following the science, law, and ethics of drug policy reform.

Scheduling, Prohibition, and Rescheduling

**Scheduling** refers to the legal classification of medicines and controlled substances based on their perceived medical value, safety, and potential for dependence. Under South African law, the South African Health Products Regulatory Authority (SAHPRA) assigns substances to schedules from Schedule 0 (lowest restriction, available over the counter) to Schedule 7 (highest restriction). Schedule 7 substances are deemed to have no recognised medical use and a high potential for abuse, making them generally illegal to possess, manufacture, or distribute. This mirrors international frameworks like the United Nations 1971 Convention on Psychotropic Substances, which lists psilocybin under Schedule I (the most restrictive tier).

**Prohibition** is the overarching policy framework that criminalises these activities. **Rescheduling**, by contrast, is the formal regulatory act of moving a substance from one legal category to another. For example, in 2023, Australia's Therapeutic Goods Administration (TGA) rescheduled psilocybin from a prohibited substance to a controlled medical one (Schedule 8), allowing strictly authorised psychiatrists to prescribe it for specific, treatment-resistant mental health conditions.

Decriminalisation, Legalisation, and Medical Access

These three terms represent different points on the policy spectrum, and confusing them muddies the debate. **Decriminalisation** means removing criminal penalties for the personal possession of a substance. Under decriminalisation, possessing small amounts might still result in a civil fine or a mandatory referral to a health programme, but it does not result in a criminal record or imprisonment. Crucially, decriminalisation does not create a legal market; the production and sale of the substance remain prohibited. The global debate often looks to Portugal, which decriminalised the personal use of all drugs in 2001, as a public health model.

**Legalisation** goes further: it removes legal prohibitions entirely and establishes a regulated, legal market for the production, sale, and possession of a substance. **Medical access** is a distinct, narrower framework where a substance remains prohibited for the general public but is legally available through the healthcare system for specific, diagnosed conditions. Medical access usually requires a prescription and clinical oversight, as seen in the emerging regulatory models for psychedelics. In South Africa, the 2018 Constitutional Court judgment regarding the private possession and cultivation of cannabis by adults is often discussed as a judicial step toward decriminalisation, though it did not legalise commercial trade.

Prodrug, Classic Psychedelics, and Breakthrough Therapy

Understanding the clinical and regulatory debate requires a grasp of a few key scientific terms. A **prodrug** is a compound that is biologically inactive when ingested but is converted by the body's metabolism into an active drug. Psilocybin is a classic example of a prodrug: once ingested, it is rapidly metabolised in the liver into psilocin, which is the compound that actually crosses the blood-brain barrier and interacts with serotonin receptors to produce psychedelic effects. Recognising this distinction is important in pharmacology, as researchers often study the effects and mechanisms of psilocin rather than psilocybin itself.

**Classic psychedelics** refers to a specific group of substances that act primarily as agonists (activators) at the serotonin 2A (5-HT2A) receptor in the brain. This group includes psilocybin, LSD, DMT, and mescaline. They are grouped together because they share similar psychological effects and neurological mechanisms, distinguishing them from other psychoactive substances like stimulants or dissociatives. **Breakthrough Therapy** is a formal regulatory designation used by the United States Food and Drug Administration (FDA). It is granted to an investigational drug intended to treat a serious condition where preliminary clinical evidence indicates it may be substantially better than existing therapies. Psilocybin has received this designation for treatment-resistant depression, which means it is eligible for expedited regulatory review, though it remains a controlled substance outside of approved clinical trials.

Harm Reduction, Set and Setting, and Integration

Beyond law and pharmacology, policy debates also involve clinical and public health frameworks. **Harm reduction** is a public health philosophy that prioritises minimising the negative consequences of drug use—such as accidental injury or psychological distress—rather than relying solely on prohibition and punishment. In the context of psychedelics, harm reduction often involves public education about safety risks and the establishment of supportive environments, rather than turning a blind eye to use.

**Set and setting** is a foundational concept in psychedelic research, referring to the "set" (the individual's mindset, expectations, and psychological state) and the "setting" (the physical, social, and cultural environment in which the experience takes place). Modern clinical trials rigorously control set and setting to ensure participant safety, distinguishing contemporary research from the uncontrolled recreational use of the past. **Integration** is the therapeutic process of working with a guide or therapist to make sense of a psychedelic experience and translate its psychological insights into lasting changes in daily life. In regulated medical models, integration is viewed as an essential part of the overall therapy, extending care well beyond the acute effects of the substance.